Pruritus in chronic kidney disease.
Journal
Current opinion in nephrology and hypertension
ISSN: 1473-6543
Titre abrégé: Curr Opin Nephrol Hypertens
Pays: England
ID NLM: 9303753
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
aheadofprint:
15
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
29
7
2022
Statut:
ppublish
Résumé
Among the many difficult symptoms that patients with kidney disease experience, pruritus is one of the most frequent and troubling. Because a substantial amount of new information has accumulated, we seek here to review the subject. Pruritus is not only a common problematic symptom among patients with kidney disease, but its considerably more frequent than nephrologists recognize. The result for patients is not just uncomfortable itch but degraded quality of life as well. The pathogenesis is increasingly understood, but many aspects remain to be fully resolved. Importantly, research is progressing on treatment, leading to the first approved medication in the United States, difelikefalin, in August, 2021. As nephrology is progressing to a greater focus on patient symptoms, recognition of the importance of pruritus has led to increased interest and improved diagnosis and treatment options.
Identifiants
pubmed: 35894277
doi: 10.1097/MNH.0000000000000824
pii: 00041552-202209000-00007
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
435-441Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Verduzco HA, Shirazian S. CKD-associated pruritus: new insights into diagnosis, pathogenesis, and management. Kidney Int Rep 2020; 5:1387–1402.
Sukul N, Karaboyas A, Csomor PA, et al. Self-reported pruritus and clinical, dialysis-related, and patient-reported outcomes in hemodialysis patients. Kidney Med 2020; 3:42–53.e1.
Hu X, Sang Y, Yang M, et al. Prevalence of chronic kidney disease-associated pruritus among adult dialysis patients: a meta-analysis of cross-sectional studies. Medicine (Baltimore) 2018; 97:e10633.
Rayner HC, Larkina M, Wang M, et al. International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis. Clin J Am Soc Nephrol 2017; 12:2000–2007.
Schricker S, Weisshaar E, Kupfer J, Mettang T. Prevalence of pruritus in a single cohort of long-term kidney transplant recipients. Acta Derm Venereol 2020; 100:adv00066.
Ting SW, Fan PC, Lin YS, et al. Uremic pruritus and long-term morbidities in the dialysis population. PLoS One 2020; 15:e0241088.
Grochulska K, Ofenloch RF, Mettang T, Weisshaar E. Mortality of haemodialysis patients with and without chronic itch: a follow-up study of the German Epidemiological Hemodialysis Itch Study (GEHIS). Acta Derm Venereol 2019; 99:423–428.
Susel J, Batycka-Baran A, Reich A, et al. Uraemic pruritus markedly affects the quality of life and depressive symptoms in haemodialysis patients with end-stage renal disease. Acta Derm Venereol 2014; 94:276–281.
Mathur VS, Lindberg J, Germain M, et al. A longitudinal study of uremic pruritus in hemodialysis patients. Clin J Am Soc Nephrol 2010; 5:1410–1419.
Pisoni RL, Wikstrom B, Elder SJ, et al. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2006; 21:3495–3505.
Ramakrishnan K, Bond TC, Claxton A, et al. Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms. Int J Nephrol Renovasc Dis 2013; 7:1–12.
Narita I, Alchi B, Omori K, et al. Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int 2006; 69:1626–1632.
Combs SA, Teixeira JP, Germain MJ. Pruritus in kidney disease. Semin Nephrol 2015; 35:383–391.
Mettang T, Kremer AE. Uremic pruritus. Kidney Int 2015; 87:685–691.
Weisbord SD, Fried LF, Mor MK, et al. Renal provider recognition of symptoms in patients on maintenance hemodialysis. Clin J Am Soc Nephrol 2007; 2:960–967.
Schricker S, Kimmel M. Unravelling the pathophysiology of chronic kidney disease-associated pruritus. Clin Kidney J 2021; 14: (Suppl 3): i23–i31.
Yosipovitch G, Reis J, Tur E, et al. Sweat secretion, stratum corneum hydration, small nerve function and pruritus in patients with advanced chronic renal failure. Br J Dermatol 1995; 133:561–564.
Kim SJ, Zhang X, Cho SB, et al. Uremic solutes of indoxyl sulfate and p -cresol enhance protease-activated receptor-2 expression in vitro and in vivo in keratinocytes. Hum Exp Toxicol 2021; 40:113–123.
Mazumder MK, Paul R, Bhattacharya P, Borah A. Neurological sequel of chronic kidney disease: from diminished acetylcholinesterase activity to mitochondrial dysfunctions, oxidative stress and inflammation in mice brain. Sci Rep 2019; 9:3097.
Fantini F, Baraldi A, Sevignani C, et al. Cutaneous innervation in chronic renal failure patients. An immunohistochemical study. Acta Derm Venereol 1992; 72:102–105.
Szepietowski J, Thepen T, van Vloten WA, et al. Pruritus and mast cell proliferation in the skin of haemodialysis patients. Inflamm Res 1995; 44: (Suppl 1): S84–S85.
Ko MJ, Yang JY, Wu HY, et al. Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial. Br J Dermatol 2011; 165:633–639.
Virga G, Visentin I, La Milia V, et al. Inflammation and pruritus in haemodialysis patients. Nephrol Dial Transplant 2002; 17:2164–2169.
Kinugasa E, Igawa K, Shimada H, et al. Antipruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study. Clin Exp Nephrol 2021; 25:875–884.
Ständer S, Gunzer M, Metze D, et al. Localization of mu-opioid receptor 1A on sensory nerve fibers in human skin. Regul Pept 2002; 110:75–83.
Paul LB, Mei B-Q. Akiyama T, Carstens E. CRC Press/Taylor & Francis, Itch: mechanisms and treatment. Boca Raton, FL:2014.
Wieczorek A, Krajewski P, Kozioł-Gałczyńska M, et al. Opioid receptors expression in the skin of haemodialysis patients suffering from uraemic pruritus. J Eur Acad Dermatol Venereol 2020; 34:2368–2372.
Heurich M, Mousa SA, Lenzner M, et al. Influence of pain treatment by epidural fentanyl and bupivacaine on homing of opioid-containing leukocytes to surgical wounds. Brain Behav Immun 2007; 21:544–552.
Binder W, Mousa SA, Sitte N, et al. Sympathetic activation triggers endogenous opioid release and analgesia within peripheral inflamed tissue. Eur J Neurosci 2004; 20:92–100.
Weisshaar E, Weiss M, Passlick-Deetjen J, et al. Laboratory and dialysis characteristics in hemodialysis patients suffering from chronic itch--results from a representative cross-sectional study. BMC Nephrol 2015; 16:184.
Hampers CL, Katz AI, Wilson RE, Merrill JP. Disappearance of “uremic” itching after subtotal parathyroidectomy. N Engl J Med 1968; 279:695–697.
Shirazian S, Kline M, Sakhiya V, et al. Longitudinal predictors of uremic pruritus. J Ren Nutr 2013; 23:428–431.
Wang TJ, Lan LC, Lu CS, et al. Efficacy of narrowband ultraviolet phototherapy on renal pruritus. J Clin Nurs 2013; 23:1593–1602.
Cheikh Hassan HI, Brennan F, Collett G, et al. Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. J Pain Symptom Manage 2015; 49:782–789.
Rayner H, Baharani J, Smith S, et al. Uraemic pruritus: relief of itching by gabapentin and pregabalin. Nephron Clin Pract 2012; 122:75–79.
Shavit L, Grenader T, Lifschitz M, Slotki I. Use of pregabalin in the management of chronic uremic pruritus. J Pain Symptom Manage 2013; 45:776–781.
Hercz D, Jiang SH, Webster AC. Interventions for itch in people with advanced chronic kidney disease. Cochrane Database Syst Rev 2020; 12:Cd011393.
Lau T, Leung S, Lau W. Gabapentin for uremic pruritus in hemodialysis patients: a qualitative systematic review. Can J Kidn Health Dis 2016; 3:14–25.
Endoh T, Matsuura H, Tajima A, et al. Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist”. Life Sci 1999; 65:1685–1694.
Kumagai H, Ebata T, Takamori K, et al. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 2010; 25:1251–1257.
Albert-Vartanian A, Boyd MR, Hall AL. Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? J Clin Pharm Ther 2016; 41:371–382.
Cowan A, Kehner GB, Inan S. Targeting itch with ligands selective for κ opioid receptors. Handb Exp Pharmacol 2015; 226:291–314.
Fishbane S, Mathur V, Germain MJ, et al. Trial investigators. Kidney Int Rep 2020; 5:600–610.
Vernon MK, Swett LL, Speck RM, et al. Psychometric validation and meaningful change thresholds of the Worst Itching Intensity Numerical Rating Scale for assessing itch in patients with chronic kidney disease-associated pruritus. J Patient Rep Outcomes 2021; 5:134.
Fishbane S, Jamal A, Munera C, et al. KALM-1 Trial Investigators. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med 2020; 382:222–232.